Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by jewel1on Sep 13, 2010 10:14am

442 Views

Post# 17440382

RE: RE: Will .14 become the new level of support?

It has been torture holding QEI up to this point. The delay in the financing closing certainly delayed any positive movement in the stock, but I am encouraged that it is starting to move. I think that there is a lot of potential in QEI but my frustration has been that my timing has been off with this stock. I hope that they can get their drilling going ASAP and that someone from Sprott shows up on BNN sooner than later touting it again.

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading